Mirtazapine Viatris (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and by antagonising 5‑HT2 and 5‑HT3 receptors while also blocking histamine H1 receptors. This combination leads to indirect stimulation of 5‑HT1A receptors, enhancing serotonin activity and producing an antidepressant effect.

The appropriate dose of Mirtazapine Viatris is determined by the prescribing clinician based on the individual’s clinical condition, response to therapy, and tolerability. Dosage adjustments are made according to professional guidelines and patient-specific factors.

The safety of mirtazapine in pregnancy and lactation has not been definitively established. Healthcare providers should weigh potential benefits against possible risks and consider alternative treatments when appropriate. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss their situation with a qualified medical professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements), and assistance with import documentation.

Mirtazapine belongs to the NaSSA class, differing from selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs) by its unique receptor profile. It often produces strong sedative effects and appetite stimulation, which can be advantageous for patients with insomnia or weight loss, but may be less suitable for those concerned about weight gain.

Mirtazapine Viatris should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Mirtazapine Viatris is taken orally, usually once daily in the evening due to its sedative properties. The tablet should be swallowed whole with water and not chewed or crushed, unless otherwise directed by a healthcare professional.

Serious risks include the rare development of agranulocytosis, severe hypotension, seizures, hepatic dysfunction, and the emergence or worsening of suicidal thoughts. Patients should be monitored closely for any signs of these conditions, and immediate medical attention is required if they occur.

Mirtazapine is contraindicated in patients who have a known hypersensitivity to mirtazapine or any of its excipients. It should also be avoided in individuals currently taking monoamine oxidase inhibitors (MAOIs) or those with a history of severe hepatic impairment without appropriate medical supervision.